Astellas Pharma Inc (ALPMF) 14.3170 $ALPMF
Global Endocarditis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, NexusCRO, Astellas Pharma - Research and Markets
BusinessWire - Thu Jun 02, 7:43AM CDT
Research and Markets has announced the addition of the "Endocarditis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.64 (-0.18)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.80 (-0.17)
Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
BusinessWire - Tue May 24, 7:00PM CDT
--Thunderbolt Pharma, Inc., will use technology to develop potential treatments for systemic lupus erythematosus and other B-cell mediated disorders
BXLT: 46.02 (-0.18)
Immunomic Therapeutics (ITI) Named "Company of the Year" by the Tech Council of Maryland
PR Newswire - Mon May 16, 11:14AM CDT
At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night's industry celebration.
Global Varicella Zoster (HHV-3) Infections Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Merck, TSRL - Research and Markets
BusinessWire - Wed May 11, 12:52PM CDT
Research and Markets has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016" report to their offering.
MRK: 56.64 (-0.18)
Pipeline of Gastric Ulcers Market Reviewed for H1 2016 in New Global Research Report
PR Newswire - Mon May 02, 7:30AM CDT
New market research report titled "Gastric Ulcers - Pipeline Review, H1 2016" help enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Arterial Thrombosis Pipeline Report H1 2016 - Review of the Drug Profiles from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai Co., Johnson & Johnson & Sanofi - Research and Markets
BusinessWire - Fri Apr 29, 8:34AM CDT
Research and Markets has announced the addition of the "Arterial Thrombosis - Pipeline Review, H1 2016" report to their offering.
BMY: 72.89 (-0.11)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.15 (-0.15), OCAT: 8.47 (+0.01), ZBH: 121.82 (-1.09), PFE: 34.69 (-0.18), LLY: 75.12 (-0.34), GSK: 42.89 (+0.48), GLPG: 60.01 (+2.51), AXSM: 7.66 (+0.16), OMER: 11.66 (-0.25), CANF: 3.07 (+0.17), AST: 3.21 (+0.01), AKTX: 14.00 (-0.19)
Astellas and the CNTRP Continue Partnership and Commitment to Canadian Research Innovation
CNW Group - Wed Apr 27, 7:00AM CDT
Recipients of the second annual Research Innovation Grant competition announced
Astellas Oncology C3 Prize(TM) to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
PR Newswire - Tue Apr 26, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) announced today the launch of the C3 Prize(TM), a challenge designed to inspire non-medicine innovations that improve the cancer care experience for patients, caregivers and loved ones. Entries will be accepted through August 8 and following a live pitch to a panel of judges including Robert Herjavec, star of ABC's Emmy Award-winning hit television show Shark Tank, three winners will be awarded a total of $100,000 in grants as well as membership to healthcare technology incubator MATTER to bring their ideas to life. The C3 Prize was announced to a group of 1,100 global leaders in cancer care gathered at the World Medical Innovation Forum organized by Partners HealthCare.
Astellas Pharma Canada Named as a Great Place to Work®
CNW Group - Fri Apr 22, 7:00AM CDT
Astellas Pharma Canada, Inc. (Astellas), the Canadian subsidiary of Tokyo based Astellas Pharma, Inc. (Tokyo: 4503), announced today that the company is being recognized as one of this year's Best Workplaces in Canada. The annual award, which is administered by the Great Place to Work(®) Institute Canada, recognizes employers across the country for creating and fostering exemplary workplace environments. This list, and related stories, will appear in a special national report on Friday, April 22, 2016 in The Globe and Mail.
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
PR Newswire - Thu Apr 07, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide in the European label for XTANDI® (enzalutamide) capsules.
MDVN: 60.80 (-0.17)
Nocturia Therapeutics Pipeline Review, H1 2016 Featuring Allergan Plc, Astellas Pharma, Sumitomo Dainippon Pharma & Vantia Therapeutics - Research and Markets
BusinessWire - Thu Mar 24, 2:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d75sd8/nocturia) has announced the addition of the "Nocturia - Pipeline Review, H1 2016" report to their offering.
AGN: 246.96 (-0.16)
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
PR Newswire - Thu Mar 24, 6:10AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that the ARCHES (AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer) Phase III registrational trial, which will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated and the first patient has been randomized.
MDVN: 60.80 (-0.17)
7MM Clostridium difficile Infections (CDI) Worth USD 1.5 Billion by 2024 - Analysis, Technologies & Forecasts Report 2016-2024 - Key Vendors: Merck, Astellas Pharma, Sanofi - Research and Markets
BusinessWire - Tue Mar 08, 12:06PM CST
Research and Markets (http://www.researchandmarkets.com/research/svqc4f/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024" report to their offering.
MRK: 56.64 (-0.18)
Post Operative Nausea & Vomiting Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Acacia Pharma, Helsinn Holding - Research and Markets
BusinessWire - Mon Mar 07, 12:27PM CST
Research and Markets (http://www.researchandmarkets.com/research/x3vg35/post_operative) has announced the addition of the "Post Operative Nausea And Vomiting Global Clinical Trials Review, H2, 2015" report to their offering.
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
PR Newswire Europe - Fri Mar 04, 2:03AM CST
CHERTSEY, England, March 4, 2016 /PRNewswire/ --
Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
PR Newswire - Wed Feb 10, 8:48AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
announced today that it has successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ("Laurel" , a tender offer to purchase all issued and outstanding shares of common stock of Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" for a price of US$8.50 per share net to the stockholder in cash ("Tender Offer" . Astellas commenced the Tender Offer on November 19, 2015, U.S. Eastern Time, and the Tender Offer, as previously extended, expired at 5:00 p.m., U.S. Eastern Time, on February 9, 2016, and was not further extended. The board of directors of Astellas approved the Tender Offer on November 10, 2015.
OCAT: 8.47 (+0.01)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 29.73 (+0.06), ACH: 7.64 (-0.02), CYTR: 2.77 (-0.20), AVEO: 1.04 (unch), ARQL: 1.82 (-0.03), CTIC: 0.43 (-0.01), ARRY: 3.79 (-0.06)
Global Endocarditis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, NexusCRO, Astellas Pharma - Research and Markets
BusinessWire - Thu Jun 02, 7:43AM CDT
Research and Markets has announced the addition of the "Endocarditis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.64 (-0.18)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.80 (-0.17)
Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
BusinessWire - Tue May 24, 7:00PM CDT
--Thunderbolt Pharma, Inc., will use technology to develop potential treatments for systemic lupus erythematosus and other B-cell mediated disorders
BXLT: 46.02 (-0.18)
Immunomic Therapeutics (ITI) Named "Company of the Year" by the Tech Council of Maryland
PR Newswire - Mon May 16, 11:14AM CDT
At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night's industry celebration.
Global Varicella Zoster (HHV-3) Infections Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Merck, TSRL - Research and Markets
BusinessWire - Wed May 11, 12:52PM CDT
Research and Markets has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016" report to their offering.
MRK: 56.64 (-0.18)
Pipeline of Gastric Ulcers Market Reviewed for H1 2016 in New Global Research Report
PR Newswire - Mon May 02, 7:30AM CDT
New market research report titled "Gastric Ulcers - Pipeline Review, H1 2016" help enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Arterial Thrombosis Pipeline Report H1 2016 - Review of the Drug Profiles from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai Co., Johnson & Johnson & Sanofi - Research and Markets
BusinessWire - Fri Apr 29, 8:34AM CDT
Research and Markets has announced the addition of the "Arterial Thrombosis - Pipeline Review, H1 2016" report to their offering.
BMY: 72.89 (-0.11)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.15 (-0.15), OCAT: 8.47 (+0.01), ZBH: 121.82 (-1.09), PFE: 34.69 (-0.18), LLY: 75.12 (-0.34), GSK: 42.89 (+0.48), GLPG: 60.01 (+2.51), AXSM: 7.66 (+0.16), OMER: 11.66 (-0.25), CANF: 3.07 (+0.17), AST: 3.21 (+0.01), AKTX: 14.00 (-0.19)
Astellas and the CNTRP Continue Partnership and Commitment to Canadian Research Innovation
CNW Group - Wed Apr 27, 7:00AM CDT
Recipients of the second annual Research Innovation Grant competition announced
Astellas Oncology C3 Prize(TM) to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
PR Newswire - Tue Apr 26, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) announced today the launch of the C3 Prize(TM), a challenge designed to inspire non-medicine innovations that improve the cancer care experience for patients, caregivers and loved ones. Entries will be accepted through August 8 and following a live pitch to a panel of judges including Robert Herjavec, star of ABC's Emmy Award-winning hit television show Shark Tank, three winners will be awarded a total of $100,000 in grants as well as membership to healthcare technology incubator MATTER to bring their ideas to life. The C3 Prize was announced to a group of 1,100 global leaders in cancer care gathered at the World Medical Innovation Forum organized by Partners HealthCare.
Astellas Pharma Canada Named as a Great Place to Work®
CNW Group - Fri Apr 22, 7:00AM CDT
Astellas Pharma Canada, Inc. (Astellas), the Canadian subsidiary of Tokyo based Astellas Pharma, Inc. (Tokyo: 4503), announced today that the company is being recognized as one of this year's Best Workplaces in Canada. The annual award, which is administered by the Great Place to Work(®) Institute Canada, recognizes employers across the country for creating and fostering exemplary workplace environments. This list, and related stories, will appear in a special national report on Friday, April 22, 2016 in The Globe and Mail.
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
PR Newswire - Thu Apr 07, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide in the European label for XTANDI® (enzalutamide) capsules.
MDVN: 60.80 (-0.17)
Nocturia Therapeutics Pipeline Review, H1 2016 Featuring Allergan Plc, Astellas Pharma, Sumitomo Dainippon Pharma & Vantia Therapeutics - Research and Markets
BusinessWire - Thu Mar 24, 2:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d75sd8/nocturia) has announced the addition of the "Nocturia - Pipeline Review, H1 2016" report to their offering.
AGN: 246.96 (-0.16)
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
PR Newswire - Thu Mar 24, 6:10AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that the ARCHES (AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer) Phase III registrational trial, which will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated and the first patient has been randomized.
MDVN: 60.80 (-0.17)
7MM Clostridium difficile Infections (CDI) Worth USD 1.5 Billion by 2024 - Analysis, Technologies & Forecasts Report 2016-2024 - Key Vendors: Merck, Astellas Pharma, Sanofi - Research and Markets
BusinessWire - Tue Mar 08, 12:06PM CST
Research and Markets (http://www.researchandmarkets.com/research/svqc4f/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024" report to their offering.
MRK: 56.64 (-0.18)
Post Operative Nausea & Vomiting Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Acacia Pharma, Helsinn Holding - Research and Markets
BusinessWire - Mon Mar 07, 12:27PM CST
Research and Markets (http://www.researchandmarkets.com/research/x3vg35/post_operative) has announced the addition of the "Post Operative Nausea And Vomiting Global Clinical Trials Review, H2, 2015" report to their offering.
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
PR Newswire Europe - Fri Mar 04, 2:03AM CST
CHERTSEY, England, March 4, 2016 /PRNewswire/ --
Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
PR Newswire - Wed Feb 10, 8:48AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
announced today that it has successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ("Laurel" , a tender offer to purchase all issued and outstanding shares of common stock of Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" for a price of US$8.50 per share net to the stockholder in cash ("Tender Offer" . Astellas commenced the Tender Offer on November 19, 2015, U.S. Eastern Time, and the Tender Offer, as previously extended, expired at 5:00 p.m., U.S. Eastern Time, on February 9, 2016, and was not further extended. The board of directors of Astellas approved the Tender Offer on November 10, 2015. OCAT: 8.47 (+0.01)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 29.73 (+0.06), ACH: 7.64 (-0.02), CYTR: 2.77 (-0.20), AVEO: 1.04 (unch), ARQL: 1.82 (-0.03), CTIC: 0.43 (-0.01), ARRY: 3.79 (-0.06)
